Growth factors in gliomas: antisense and dominant negative mutant strategies
- PMID: 9440025
- DOI: 10.1023/a:1005820701709
Growth factors in gliomas: antisense and dominant negative mutant strategies
Abstract
Antisense and dominant negative mutant strategies were developed as 'magic bullets' to suppress the function of a particular gene while preserving the remaining cellular activities. While experience with these techniques has dispelled some of the 'magic', these strategies remain useful for understanding the function of particular gene products. Antisense strategies involve the administration of either a synthetic oligodeoxynucleotide or a plasmid construct which produces a sequence that is complementary to the DNA or mRNA of the gene of interest. Antisense binding should inhibit transcription or translation of the gene, and thus decrease synthesis of the protein for which the gene encodes. Conversely, dominant negative mutations inhibit activity of a gene product by encoding for a second protein which suppresses the function of the gene of interest. For example, a single mutant subunit in a multimeric protein might allow normal assembly of the protein while inhibiting its activity. The use of these techniques for investigating the role of various growth factor pathways in glial neoplasia and their potential therapeutic applications are reviewed below.
Similar articles
-
Specific gene suppression using antisense strategy for growth suppression of glioma.Med Electron Microsc. 2004 Sep;37(3):158-61. doi: 10.1007/s00795-004-0251-6. Med Electron Microsc. 2004. PMID: 15449107 Review.
-
[Approach to human glioma cells using antisense molecules].No To Shinkei. 1995 Sep;47(9):823-8. No To Shinkei. 1995. PMID: 7546930 Review. Japanese. No abstract available.
-
[Gene therapy for brain tumors: antitumor effects of introduction of antisense and tumor suppressor gene (series 2)].No Shinkei Geka. 1994 Oct;22(10):903-9. No Shinkei Geka. 1994. PMID: 7969756 Review. Japanese. No abstract available.
-
Antisense oligonucleotides in the treatment of cerebral gliomas. Review of concerning patents.Recent Pat CNS Drug Discov. 2014 Apr;9(1):2-12. doi: 10.2174/1574889809666140307113439. Recent Pat CNS Drug Discov. 2014. PMID: 24605941 Review.
-
Nucleic acid-based technologies in therapy of malignant gliomas.Curr Pharm Biotechnol. 2011 Nov;12(11):1805-22. doi: 10.2174/138920111798377067. Curr Pharm Biotechnol. 2011. PMID: 21902632 Review.
Cited by
-
Autocrine growth regulation by granulocyte colony-stimulating factor and granulocyte macrophage colony-stimulating factor in human gliomas with tumor progression.Am J Pathol. 1999 Nov;155(5):1557-67. doi: 10.1016/S0002-9440(10)65472-7. Am J Pathol. 1999. PMID: 10550313 Free PMC article.
References
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Medical